Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Status:
Terminated
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor. Giving sorafenib before
surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be
removed.
PURPOSE: This clinical trial is studying how well sorafenib works in treating patients with
locally advanced or metastatic kidney cancer.